EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study

Mizuki Shiba, Teppei Hagino iD, Akihiko Uchiyama iD, Hidehisa Saeki iD, Eita Fujimoto iD, Sei-Ichiro Motegi iD, Naoko Kanda iD

The Journal of Dermatology · 2026

DOI: 10.1111/1346-8138.70138 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Mizuki Shiba und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Dermatologic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Maruho Takagi Dermatology Foundation, Torii Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with tralokinumab for 72 weeks. Eczema area and severity index (EASI) scores were analyzed on four anatomical sites (head/neck, trunk, upper limbs, and lower limbs). Tralokinumab consistently reduced EASI on all anatomical sites. The achievement rates of EASI 75 and 100 on each site gradually increased from Week 4 to Week 72, and those on lower limbs appeared higher compared to the other sites. The percent reductions of EASI throughout 72 weeks appeared slightly lower on head and neck compared to the other sites. Week 72 achievement rate of EASI 75 on head/neck, trunk, upper limbs, or lower limbs was 80.4%, 80%, 80.3%, or 86.7%, while that of EASI 100 was 37.3%, 25.0%, 27.4%, and 40.0%, respectively. Tralokinumab reduced EASI scores through 72 weeks across different anatomical sites in AD patients. The achievement rates of EASI 75 and 100 appeared slightly higher on lower limbs compared to the other sites.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, MonoclonalDermatologic AgentsHumansFemaleMaleAdultTreatment OutcomeSeverity of Illness IndexMiddle AgedYoung AdultAdolescentInterleukin-13HeadNeckTime FactorsLower ExtremityTorsoUpper Extremity

Stichwörter der Autor:innen

atopic dermatitisinterleukin‐13real‐worldsite‐specifictralokinumab

Substanzen

tralokinumabAntibodies, MonoclonalInterleukin-13Dermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Department of Dermatology, Fujimoto Dermatology Clinic, Funabashi, Japan.

ORCID-Profile: Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei-Ichiro Motegi, Naoko Kanda

Förderung

  • Maruho Takagi Dermatology Foundation
  • Torii Pharmaceutical

Zitieren

APA

Shiba, M., Hagino, T., Uchiyama, A., Saeki, H., Fujimoto, E., Motegi, S. I., & Kanda, N. (2026). Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70138

Vancouver

Shiba M, Hagino T, Uchiyama A, Saeki H, Fujimoto E, Motegi SI, et al. Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70138

BibTeX
@article{Shiba2026,
  author = {Shiba, Mizuki and Hagino, Teppei and Uchiyama, Akihiko and Saeki, Hidehisa and Fujimoto, Eita and Motegi, Sei-Ichiro and Kanda, Naoko},
  title = {Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study},
  journal = {The Journal of Dermatology},
  year = {2026},
  doi = {10.1111/1346-8138.70138}
}
Kostenlos starten →